



Date: June 03, 2025

To The Listing Department National Stock Exchange of India Limited Exchange Plaza, Bandra – Kurla Complex Bandra (East) <u>Mumbai – 400 051</u> Stock Code : INDOCO	To The Listing Department Bombay Stock Exchange Limited Floor 25, P. J. Towers, Dalal Street, <u>Mumbai – 400 001</u> Stock Code : 532612
--	---

Dear Sir/Madam,

Subject: Press Release- Indoco Remedies Limited announces the first day launch of Ticagrelor film-coated tablets through its subsidiary in the United Kingdom

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are pleased to inform you that Indoco Remedies UK Limited, the subsidiary of our Company has officially launched Ticagrelor film-coated tablets 90mg in the United Kingdom on June 2, 2025”.

Please find enclosed herewith the press release dated June 03, 2025 in this regards and details as required under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024.

This is for your information and records.

Thanking you,
Yours faithfully,
For Indoco Remedies Limited



Ramanathan Hariharan
Company Secretary & Head- Legal



Details under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read along with SEBI Master Circular SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024

Name of the Product	Ticagrelor film-coated tablets
Date of launch	June 02, 2025
Category of the Product	Antiplatelet medication
Whether caters to domestic/ international market	International market
Name of the countries in which the Product is launched (in case of international)	United Kingdom





PRESS RELEASE

Indoco Remedies Limited announces the first day launch of Ticagrelor film-coated tablets through its subsidiary in the United Kingdom

Mumbai, June 03, 2025: Indoco announced today that its subsidiary company, Indoco Remedies UK Limited, officially launched Ticagrelor film-coated tablets 90mg in the United Kingdom on June 2, 2025. This significant addition to Indoco's portfolio will be marketed and distributed by Clarity Pharma, across the United Kingdom.

Ticagrelor film-coated tablets are indicated to reduce the chances of heart attack, stroke, myocardial infarction (MI) or diseases related to the heart or blood vessels.

"This development underscores our commitment to bringing high quality, life-saving treatments to patients in the UK", **said Ms. Aditi Kare Panandikar, Managing Director, Indoco Remedies Ltd.**

About Indoco Remedies Limited:

Indoco is a fully integrated, research-oriented pharmaceutical company with a strong global presence. The Company's turnover is US\$ 180 million with a human capital of over 6000 employees, including over 400 skilled scientists and field staff who are the strength of the organization.

The Company has 11 manufacturing facilities, 7 for FDFs and 4 for APIs, supported by a state-of-the-art R&D Centre and a CRO facility. The facilities have been approved by most of the Regulatory Authorities including USFDA and UK-MHRA. Indoco develops and manufactures a wide range of pharmaceutical products for the Indian and international markets. It generates more than 106 million prescriptions annually from over 2,40,000 doctors belonging to various specialties. Indoco has 10 domestic marketing divisions, a strong brand portfolio in various therapeutic segments including Gastro-intestinal, Respiratory, Anti-Infectives, Stomatologicals, Ophthalmic, Nutritionals, Cardiovascular, Anti-Diabetics, Pain Management, Gynaecology, etc. Top Indoco brands include Cyclopam, Febrex Plus, Sensodent-K, Karvol Plus, ATM, Oxipod, Cital, Sensiform, Sensodent-KF, Aloja, Glychek, Kidodent, Subitral, Rexitin, MCBM 69, Methycal, Dropizin, Noxa, Homide, Cal-Aid, Ninaf, Cital-Uti, Otorex, etc. On the international front, Indoco has tie-ups with large generic companies across the globe.

For more details on Indoco, you may visit www.indoco.com

For Media Enquiries, Please Contact:

Corporate Communications | +91 22 62871000

E-mail: corpcom@indoco.com

